Mary Louise Devitt
New York University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mary Louise Devitt.
International Journal of Radiation Oncology Biology Physics | 2008
Elizabeth W. Newcomb; Yevgeniy Lukyanov; M. Alonso-Basanta; Mine Esencay; Iva Smirnova; Tona Schnee; Yongzhao Shao; Mary Louise Devitt; David Zagzag; William H. McBride; Silvia C. Formenti
PURPOSE To assess the effects of noscapine, a tubulin-binding drug, in combination with radiation in a murine glioma model. METHODS AND MATERIALS The human T98G and murine GL261 glioma cell lines treated with noscapine, radiation, or both were assayed for clonogenic survival. Mice with established GL261 hind limb tumors were treated with noscapine, radiation, or both to evaluate the effect of noscapine on radioresponse. In a separate experiment with the same treatment groups, 7 days after radiation, tumors were resected and immunostained to measure proliferation rate, apoptosis, and angiogenic activity. RESULTS Noscapine reduced clonogenic survival without enhancement of radiosensitivity in vitro. Noscapine combined with radiation significantly increased tumor growth delay: 5, 8, 13, and 18 days for control, noscapine alone, radiation alone, and the combination treatment, respectively (p < 0.001). To assess the effect of the combination of noscapine plus radiation on the tumor vasculature, tubule formation by the murine endothelial 2H11 cells was tested. Noscapine with radiation significantly inhibited tubule formation compared with radiation alone. By immunohistochemistry, tumors treated with the combination of noscapine plus radiation showed a decrease in BrdU incorporation, an increase in apoptosis by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling, and a decrease in tumor vessel density compared with tumors treated with radiation alone. CONCLUSION Noscapine enhanced the sensitivity of GL261 glioma tumors to radiation, resulting in a significant tumor growth delay. An antiangiogenic mechanism contributed to the effect. These findings are clinically relevant, particularly in view of the mild toxicity profile of this drug.
International Journal of Radiation Oncology Biology Physics | 2004
Sandra Demaria; Bruce Ng; Mary Louise Devitt; James S. Babb; Noriko Kawashima; Leonard Liebes; Silvia C. Formenti
Clinical Cancer Research | 2005
Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S. Babb; James P. Allison; Silvia C. Formenti
American Journal of Respiratory and Critical Care Medicine | 2008
Khalid Puthawala; Nicos P. Hadjiangelis; S. Jacoby; Emmanuel Bayongan; Zhicheng Zhao; Zhiwei Yang; Mary Louise Devitt; Gerald S. Horan; Paul H. Weinreb; Matvey E. Lukashev; Shelia M. Violette; Kristen S. Grant; Cristina Colarossi; Silvia C. Formenti; John S. Munger
International Journal of Radiation Oncology Biology Physics | 2004
John S. Munger; Nicos P. Hadjiangelis; B. Emmanuel; Mary Louise Devitt; S.C. Formenti
International Journal of Radiation Oncology Biology Physics | 2003
Sandra Demaria; Noriko Kawashima; Mary Louise Devitt; James P. Allison; S.C. Formenti
International Journal of Radiation Oncology Biology Physics | 2005
Sandra Demaria; Elizabeth W. Newcomb; David Zagzag; E. Lukyanov; Tona Schnee; Noriko Kawashima; Mary Louise Devitt; Silvia C. Formenti
International Journal of Radiation Oncology Biology Physics | 2004
Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S. Babb; James P. Allison; S.C. Formenti
International Journal of Radiation Oncology Biology Physics | 2003
Stella C. Lymberis; Jennifer M. Roth; R Diaz; D.Y Rodriguez; A Zelmanovich; Mary Louise Devitt; Peter C. Brooks; S.C. Formenti
Archive | 2007
Khalid Puthawala; Nicos P. Hadjiangelis; S. Jacoby; Emmanuel Bayongan; Zhicheng Zhao; Zhiwei Yang; Mary Louise Devitt; Gerald S. B. Horan; Paul H. Weinreb; Matvey E. Lukashev; Shelia M. Violette; K. S. Grant; Cristina Colarossi; Silvia C. Formenti; John S. Munger